ARMT1

Across TCGA pan-cancer cohorts, ARMT1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARMT1 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARMT1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARMT1 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

PDAC, GBM, and LSCC are the cancer types where ARMT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.314	0.821	.013	5	view →
GBM	DFS	Quartile	All	0.515	0.282	.037	4	view →
LSCC	DFS	Median	All	0.929	0.615	.025	2	view →
LUAD	OS	Tertile	II,III,IV	0.432	0.893	.028	2	view →
CCRCC	DFS	Median	All	0.729	0.888	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARMT1–PDAC (OS)

Open the PDAC breakdown →